title: Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
abstract: Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.
authors.affiliation: Duke Cancer Institute.
authors.forename: Rhonda L
authors.initials: RL
authors.lastname: Bitting
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Armstrong
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97
references.pmid: 20826737
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: J Clin Oncol. 1989 May;7(5):590-7
references.pmid: 2709088
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4563-71
references.pmid: 18645193
references.citation: J Clin Oncol. 2005 May 1;23(13):2918-25
references.pmid: 15860850
references.citation: J Urol. 2012 Jul;188(1):103-9
references.pmid: 22583636
references.citation: Eur J Cancer. 2010 Feb;46(3):517-25
references.pmid: 20005697
references.citation: Cancer. 2009 Aug 15;115(16):3670-9
references.pmid: 19536890
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references.pmid: 16809734
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: J Clin Oncol. 1999 Aug;17(8):2506-13
references.pmid: 10561316
references.citation: Curr Opin Urol. 2005 May;15(3):181-6
references.pmid: 15815195
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: J Immunother. 2005 Nov-Dec;28(6):517-24
references.pmid: 16224268
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Clin Oncol. 1996 Jun;14(6):1756-64
references.pmid: 8656243
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862